Sigmapharm to appeal Pfizer and BMS’ Eliquis win
Generics maker Sigmapharm Laboratories is appealing against a court win for Pfizer and Bristol Myers Squibb over patents for blood-thinner Eliquis.
CareDx drops transplant testing patent suit
California-based molecular diagnostics company CareDx and Stanford University have dropped their patent infringement suit against Tai Diagnostics, nearly five months after filing the complaint.
Gilead signs deal to license new cancer treatment
Gilead Sciences has unveiled an agreement with Jounce Therapeutics to exclusively develop and license its antibody programme, JTX-1811, which is designed to fight cancer cells.
Kite says $1.2 billion Juno award will ‘kill innovation’
Gilead Sciences division Kite Pharma wants a federal appeals court to reverse a $1.2 billion patent award in favour of Juno Pharmaceuticals and a cancer research institute.
Fed Circuit affirms cancellation of Anacor antifungal patents
Anacor Pharmaceuticals has unsuccessfully challenged the invalidation of four patents covering Kerydin, an antifungal treatment for nails.
European Commission's first deal for COVID-19 vaccine takes effect
The European Commission’s first ever contract to secure a COVID-19 vaccine came into force on August 27, after it signed a deal with pharmaceutical company AstraZeneca.
Genentech to face revived Hemlibra claims
Genentech and Chugai Pharmaceutical will have to face claims that its haemophilia drug Hemlibra (emicizumab-kxwh) infringed a patent owned by Takeda subsidiary Baxalta.
BMS to acquire Forbius in oncology expansion
Bristol Myers Squibb has announced a deal to acquire protein engineering company Forbius, including its portfolio of protein inhibitors.
Amgen urges Fed Circuit to deny Sandoz petition
Amgen’s subsidiary Immunex has called on the US Court of Appeals for the Federal Circuit to reject Sandoz’s request for an en banc rehearing of a dispute over biologic Enbrel.
Teva charged in DoJ antitrust probe into generic drug price-fixing
Teva Pharmaceuticals has been charged with conspiring to fix prices, rig bids, and allocate customers for generic drugs, the US Department of Justice has announced.
